Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There is no report upon the remote surgery of radical prostatectomy and comparisons between local surgeries. This study aims to evaluate the feasibility and safety of the innovative remote tele-surgical robotic platforms in performing radical prostatectomy.
Methods: The study comprised 13 patients diagnosed with prostate cancer who underwent remote radical prostatectomy using a 5 G wireless network and the innovative remote robotic systems (Tele-RARP). Additionally, the research involved 31 patients who underwent radical prostatectomy with the local Toumai robotic system (TM-RARP) between October 2022 and April 2024, and 36 patients who underwent radical prostatectomy with the da Vinci Xi platform (Xi-RARP) during the same period under the supervision of the same surgical team. Data on demographics, perioperative factors, clinicopathologic information, and postoperative results were collected for a total of 80 patients.
Results: The completion of 13 Tele-RARP procedures was successful without significant intraoperative or postoperative issues. No instances of intraoperative blood transfusion or surgical conversion were reported. The operation, console, and docking time for both the remote and local surgeries showed minimal differences. Neither local nor remote surgery nor da Vinci Xi surgery exhibited significant variations in terms of blood loss, intraoperative complications, or postoperative prognosis. Both TM-RARP and Tele-RARP presented very manageable task loads.
Conclusions: Performing tele-surgical robotic-assisted radical prostatectomy using the innovative Toumai and Edge robotic surgical systems via a 5 G wireless network is not only feasible but also safe.
Registration Number: ChiCTR2400085386, ChiCTR2300077721.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41391-025-01004-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Time to Prostate-Specific Antigen Failure as a Unique Prognosticator of Overall Survival in Biochemically Recurrent Prostate Cancer Patients Undergoing Radical Prostatectomy.
Adv Urol
August 2025
Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
In biochemically recurrent prostate cancer (BRPC), no definitive independent prognostic factors were reported. This study aimed to identify the factors impacting overall survival (OS) in patients with BRPC after radical prostatectomy (RP). Among 610 consecutive patients who underwent RP between January 2000 and December 2019, with follow-up through December 2024, 152 (25%) patients who developed BRPC were analyzed.
View Article and Find Full Text PDFSurgical Implications of Prior Inguinal Hernia Repair in Extraperitoneal Radical Prostatectomy.
JSLS
September 2025
Department of Urology, University of Health Sciences Medical Faculty of Kayseri, Kayseri City Hospital, Kayseri, Turkiye. (Drs. Golbasi, Karadag, Elmaagac).
Background: Inguinal hernia repair (IHR) is a common procedure, and patients with a history of IHR may later require radical prostatectomy. Prior IHR can complicate prostatectomy by altering anatomy, but its impact on extraperitoneal laparoscopic radical prostatectomy (ELRP) remains unclear. This study evaluates the feasibility and outcomes of ELRP in patients with prior IHR.
View Article and Find Full Text PDFUnveiling rare metastasis in prostate cancer: The role of PSMA-PET and MRI in detecting penile involvement - A case report and literature review.
Urol Case Rep
November 2025
Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità University Hospital, 28100, Novara, Italy.
The aim of this study is to report a case of penile metastasis from prostate carcinoma, as it represents a very rare occurrence that clinicians should be aware of. We report a case of a 68-year-old patient affected by prostate cancer who has performed a PSMA-PET after radical prostatectomy for PSA elevation, which revealed a suspected uptake in the corpora cavernosa and corpora spongiosum, followed by multiparametric MRI examination with focus on penile involvement.
View Article and Find Full Text PDFCD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.
Histol Histopathol
September 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.
Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence.